Consider sequential AR-targeted therapy or chemotherapy depending on AR-V7 status Order the test after a patient fails an AR-targeted therapy This ad depicts one possible mCRPC treatment path. mCRPC = metastatic castration-resistant prostate cancer. Oncotype DX AR-V7 Nucleus Detect and Oncotype IQ are trademarks of Genomic Health Inc., an Exact Sciences corporation. Exact Sciences is a registered trademark of Exact Sciences corporation. All other trademarks are the properties of their respective owners.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.